Feb 26, 2019 Cellectar Reports Financial Results for Year Ended December 31, 2018 and Provides a Corporate Update Learn More
Feb 25, 2019 Cellectar Reports Positive Top-line Response Rate of 30% from R/R Multiple Myeloma Cohort in Ongoing Phase 2 Study of CLR 131 Learn More
Jan 23, 2019 Cellectar Biosciences to Present at NobleConXV, Noble Capital Markets’ Fifteenth Annual Investor Conference Learn More